FRX Forest Road Acquisition Corp

NEW YORK, May 18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that its Board of Directors has approved a new share repurchase program for up to an additional 25 million shares of its common stock. The authorization will become effective immediately and has no set expiration date. The Company expects to make the repurchases from time to time in the open market depending on market conditions. (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) The new program is in addition to two previously announced and completed share repurchase programs: a 20 million share repurchase program announced on July 20, 2004 and expanded to 30 million shares on December 14, 2004 as well as a 25 million share repurchase program announced May 10, 2006. About Forest Laboratories Forest Laboratories (http://www.frx.com/) is a US-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. *Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany. Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2005, and on form 10-Q for the periods ended June 30 ,2005, September 30, 2005 and December 31, 2005. http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO DATASOURCE: Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice President - Investor Relations, +1-212-224-6714, Web site: http://www.frx.com/

Copyright